Vinorelbine (Navelbine) for Mesothelioma

Vinorelbine, sold under the brand name Navelbine, is a semi-synthetic vinca alkaloid chemotherapy drug used as a second-line treatment option for patients with malignant pleural mesothelioma whose disease has progressed after first-line pemetrexed-based chemotherapy. Unlike pemetrexed, which targets DNA synthesis enzymes, vinorelbine works by disrupting the microtubule structures that cells need to divide, effectively halting mitosis in cancer cells.¹

Vinorelbine belongs to the same drug family as vincristine and vinblastine, all derived from the periwinkle plant (Catharanthus roseus). It was originally developed and approved for non-small cell lung cancer in 1994, but its activity against mesothelioma has been demonstrated in several phase II clinical trials. As a single agent, vinorelbine produces objective response rates of approximately 16–24% in mesothelioma patients, with disease stabilization in an additional 30–50% of cases.²

One of vinorelbine's practical advantages is the availability of an oral formulation — vinorelbine capsules — which allows patients to receive treatment at home rather than requiring intravenous infusion visits. This is particularly valuable for mesothelioma patients managing fatigue and reduced mobility, as it decreases the burden of frequent hospital trips. However, the oral formulation is more commonly used in Europe and may not be available at all treatment centers in the United States.³

In current mesothelioma treatment algorithms, vinorelbine is most commonly considered when patients have progressed on or cannot tolerate platinum/pemetrexed therapy and are not candidates for immunotherapy with nivolumab and ipilimumab. It may also be combined with cisplatin as an alternative first-line doublet in rare cases where pemetrexed is contraindicated.²

Vinorelbine is used in several treatment contexts for mesothelioma, predominantly as a second-line option:²

Second-Line Single-Agent Vinorelbine

The most common use of vinorelbine in mesothelioma is as a single agent for patients who have progressed after first-line platinum/pemetrexed:¹

• Intravenous dosing — 25–30 mg/m² administered weekly or on Days 1 and 8 of a 21-day cycle
• Oral dosing — 60–80 mg/m² weekly (where available)
• Duration — Continued until disease progression or unacceptable toxicity
• Monitoring — Complete blood count before each dose; hold treatment if neutrophil count is below 1,500/mm³

Key Clinical Trial Data

Several phase II trials have evaluated vinorelbine in mesothelioma:²

• Stebbing et al. (2009) — 63 previously treated patients received single-agent vinorelbine; overall response rate 16%, median survival 9.6 months, disease control rate 66%
• Muers et al. (MS01 trial, 2008) — Compared active symptom control alone vs. active symptom control plus vinorelbine or mitomycin/vinblastine/cisplatin; vinorelbine showed a trend toward improved survival
• Zucali et al. (2014) — Vinorelbine as second-line therapy showed median progression-free survival of 2.3 months and overall survival of 6.2 months

Combination Regimens

Vinorelbine has been combined with cisplatin as an alternative first-line doublet, achieving response rates of approximately 30% in small phase II studies. It has also been studied in combination with gemcitabine for relapsed disease, though combination regimens in the second-line setting carry increased toxicity burden.⁴

As a second-line agent, vinorelbine offers modest but meaningful benefits for mesothelioma patients who have exhausted first-line options:²

• Objective response rate — 16–24% as a single agent, meaning roughly 1 in 5 patients experience measurable tumor shrinkage
• Disease control rate — 50–66%, including patients with stable disease who do not experience tumor growth
• Median overall survival — 6–10 months from start of second-line vinorelbine therapy
• Symptom improvement — Many patients report improved dyspnea and pain even without measurable tumor shrinkage

Vinorelbine is generally better tolerated than many chemotherapy drugs, but patients should be aware of its side effects and management strategies:³

• Neutropenia — The most significant side effect, affecting 30–50% of patients at grade 3–4 severity. Weekly blood counts are essential. Growth factor support (G-CSF) may be used to maintain dose intensity
• Fatigue — Common and cumulative over treatment cycles. Patients should plan rest periods and pace daily activities
• Constipation — A class effect of vinca alkaloids due to autonomic neuropathy. Prophylactic laxatives (senna, docusate) are recommended from the start of treatment
• Injection site reactions — Vinorelbine is a vesicant and can cause severe tissue damage if it leaks outside the vein. IV administration should use a large vein or central line, and any pain at the injection site must be reported immediately
• Peripheral neuropathy — Mild numbness or tingling in the extremities occurs in 10–20% of patients but is typically less severe than with cisplatin
• Nausea — Mild to moderate; vinorelbine is considered a low-emetogenic agent. Anti-nausea medication is typically effective